Jacques J M Van Dongen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1286184/publications.pdf Version: 2024-02-01

		2962	3782
404	39,367	96	185
papers	citations	h-index	g-index
412	412	412	29158
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	High-Sensitive TRBC1-Based Flow Cytometric Assessment of T-Cell Clonality in Tαβ-Large Granular Lymphocytic Leukemia. Cancers, 2022, 14, 408.	1.7	10
2	Age and Primary Vaccination Background Influence the Plasma Cell Response to Pertussis Booster Vaccination. Vaccines, 2022, 10, 136.	2.1	11
3	Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels. Cancers, 2022, 14, 473.	1.7	3
4	Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study. Cancers, 2022, 14, 1583.	1.7	11
5	pmTR database: population matched (pm) germline allelic variants of T-cell receptor (TR) loci. Genes and Immunity, 2022, 23, 99-110.	2.2	2
6	Quality Assessment of a Large Multi-Center Flow Cytometric Dataset of Acute Myeloid Leukemia Patients—A EuroFlow Study. Cancers, 2022, 14, 2011.	1.7	3
7	Population matched (pm) germline allelic variants of immunoglobulin (IG) loci: Relevance in infectious diseases and vaccination studies in human populations. Genes and Immunity, 2021, 22, 172-186.	2.2	14
8	Proteomics for Low Cell Numbers: How to Optimize the Sample Preparation Workflow for Mass Spectrometry Analysis. Journal of Proteome Research, 2021, 20, 4217-4230.	1.8	16
9	Anti-TRBC1 Antibody-Based Flow Cytometric Detection of T-Cell Clonality: Standardization of Sample Preparation and Diagnostic Implementation. Cancers, 2021, 13, 4379.	1.7	17
10	Flow Cytometry Immunophenotyping for Diagnostic Orientation and Classification of Pediatric Cancer Based on the EuroFlow Solid Tumor Orientation Tube (STOT). Cancers, 2021, 13, 4945.	1.7	5
11	Longitudinal Dynamics of Human B-Cell Response at the Single-Cell Level in Response to Tdap Vaccination. Vaccines, 2021, 9, 1352.	2.1	2
12	Reply to the Commentary on population matched (pm) germline allelic variants of immunoglobulin (IG) loci: relevance in infectious diseases and vaccination studies in human populations. Genes and Immunity, 2021, 22, 339-342.	2.2	0
13	The presence of CLL-associated stereotypic B cell receptors in the normal BCR repertoire from healthy individuals increases with age. Immunity and Ageing, 2019, 16, 22.	1.8	17
14	Combined cellular and soluble mediator analysis for improved diagnosis of vitreoretinal lymphoma. Acta Ophthalmologica, 2019, 97, 626-632.	0.6	16
15	CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. Cytometry Part B - Clinical Cytometry, 2019, 96, 134-142.	0.7	82
16	Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood, 2019, 133, 494-497.	0.6	32
17	Frequent issues and lessons learned from EuroFlow QA. Journal of Immunological Methods, 2019, 475, 112520.	0.6	26
18	Selection and validation of antibody clones against IgG and IgA subclasses in switched memory B-cells and plasma cells. Journal of Immunological Methods, 2019, 475, 112372.	0.6	17

#	Article	IF	CITATIONS
19	How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers. Journal of Immunological Methods, 2019, 475, 112388.	0.6	23
20	Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia. Journal of Immunological Methods, 2019, 475, 112429.	0.6	40
21	Optimization and testing of dried antibody tube: The EuroFlow LST and PIDOT tubes as examples. Journal of Immunological Methods, 2019, 475, 112287.	0.6	29
22	Lot-to-lot stability of antibody reagents for flow cytometry. Journal of Immunological Methods, 2019, 475, 112294.	0.6	20
23	The EuroFlow PID Orientation Tube for Flow Cytometric Diagnostic Screening of Primary Immunodeficiencies of the Lymphoid System. Frontiers in Immunology, 2019, 10, 246.	2.2	100
24	Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. Journal of Allergy and Clinical Immunology, 2018, 141, 2208-2219.e16.	1.5	217
25	<i>In Vitro</i> Measles Virus Infection of Human Lymphocyte Subsets Demonstrates High Susceptibility and Permissiveness of both Naive and Memory B Cells. Journal of Virology, 2018, 92, .	1.5	43
26	A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood, 2018, 131, 955-962.	0.6	61
27	<scp>CD</scp> 38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy. British Journal of Haematology, 2018, 180, 292-296.	1.2	18
28	Flow cytometric assessment of leukocyte kinetics for the monitoring of tissue damage. Clinical Immunology, 2018, 197, 224-230.	1.4	11
29	Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment. Neuro-Oncology, 2018, 20, 1494-1504.	0.6	50
30	Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia. Leukemia, 2018, 32, 2701-2705.	3.3	19
31	Deficiencies in the CD19 complex. Clinical Immunology, 2018, 195, 82-87.	1.4	17
32	Next-Generation Sequencing Analysis of the Human TCRγδ+ T-Cell Repertoire Reveals Shifts in Vγ- and Vδ-Usage in Memory Populations upon Aging. Frontiers in Immunology, 2018, 9, 448.	2.2	31
33	Introduction to the diagnosis and classification of monocyticâ€lineage leukemias by flow cytometry. Cytometry Part B - Clinical Cytometry, 2017, 92, 218-227.	0.7	44
34	Genetic defects in PI3KĨ´affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections. Clinical Immunology, 2017, 176, 77-86.	1.4	80
35	Detailed immunophenotyping of Bâ€cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection. British Journal of Haematology, 2017, 178, 257-266.	1.2	37
36	High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges. Journal of Immunology, 2017, 198, 3765-3774.	0.4	61

#	Article	IF	CITATIONS
37	Human IgC2―and IgC4â€expressing memory B cells display enhanced molecular and phenotypic signs of maturity and accumulate with age. Immunology and Cell Biology, 2017, 95, 744-752.	1.0	49
38	Understanding the reconstitution of the Bâ€cell compartment in bone marrow and blood after treatment for Bâ€cell precursor acute lymphoblastic leukaemia. British Journal of Haematology, 2017, 178, 267-278.	1.2	8
39	Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood, 2017, 129, 347-357.	0.6	323
40	Effects of nongenetic factors on immune cell dynamics in early childhood: The Generation R Study. Journal of Allergy and Clinical Immunology, 2017, 139, 1923-1934.e17.	1.5	34
41	Circulating T Cells of Patients with Nijmegen Breakage Syndrome Show Signs of Senescence. Journal of Clinical Immunology, 2017, 37, 133-142.	2.0	13
42	Antigen receptor sequencing of paired bone marrow samples shows homogeneous distribution of acute lymphoblastic leukemia subclones. Haematologica, 2017, 102, 1869-1877.	1.7	16
43	Ageing and latent CMV infection impact on maturation, differentiation and exhaustion profiles of T-cell receptor gammadelta T-cells. Scientific Reports, 2017, 7, 5509.	1.6	44
44	Transient reduction in IgA+ and IgG+ memory B cell numbers in young EBV-seropositive children: the Generation R Study. Journal of Leukocyte Biology, 2017, 101, 949-956.	1.5	11
45	Dysregulated signaling, proliferation and apoptosis impact on the pathogenesis of TCRγδ+ T cell large granular lymphocyte leukemia. PLoS ONE, 2017, 12, e0175670.	1.1	11
46	XLF deficiency results in reduced N-nucleotide addition during V(D)J recombination. Blood, 2016, 128, 650-659.	0.6	33
47	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood, 2016, 127, 3165-3174.	0.6	129
48	Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for <scp>MRD</scp> detection in multiple myeloma. Cytometry Part B - Clinical Cytometry, 2016, 90, 61-72.	0.7	177
49	Utility of <scp>CD</scp> 54, <scp>CD</scp> 229, and <scp>CD</scp> 319 for the identification of plasma cells in patients with clonal plasma cell diseases. Cytometry Part B - Clinical Cytometry, 2016, 90, 91-100.	0.7	47
50	Decreased IL7Rα and TdT expression underlie the skewed immunoglobulin repertoire of human B-cell precursors from fetal origin. Scientific Reports, 2016, 6, 33924.	1.6	20
51	The Human Thymus Is Enriched for Autoreactive B Cells. Journal of Immunology, 2016, 197, 441-448.	0.4	15
52	New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric Bâ€cell precursor acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 172, 769-781.	1.2	44
53	Cytomegalovirus- and Epstein-Barr Virus–Induced T-Cell Expansions in Young Children Do Not Impair Naive T-cell Populations or Vaccination Responses: The Generation R Study. Journal of Infectious Diseases, 2016, 213, 233-242.	1.9	38
54	Nuclear positioning rather than contraction controls ordered rearrangements of immunoglobulin loci. Nucleic Acids Research, 2016, 44, 175-186.	6.5	33

#	Article	IF	CITATIONS
55	Identification of checkpoints in human T-cell development using severe combined immunodeficiency stem cells. Journal of Allergy and Clinical Immunology, 2016, 137, 517-526.e3.	1.5	26
56	NGS-Based Minimal Residual Disease (MRD) after Stem Cell Transplantation (SCT) Is More Specific for Relapse Prediction Than qPCR and Suggests the Possibility of False-Positive qPCR Results. Blood, 2016, 128, 3494-3494.	0.6	1
57	Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM). Blood, 2016, 128, 373-373.	0.6	1
58	High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM). Blood, 2016, 128, 482-482.	0.6	10
59	Non-Invasive Genetic Profiling Is Highly Applicable in Multiple Myeloma (MM) through Characterization of Circulating Tumor Cells (CTCs). Blood, 2016, 128, 801-801.	0.6	2
60	Persistent subclinical immune defects in HIV-1-infected children treated with antiretroviral therapy. Aids, 2015, 29, 1745-1756.	1.0	9
61	Strategies for B-Cell Receptor Repertoire Analysis in Primary Immunodeficiencies: From Severe Combined Immunodeficiency to Common Variable Immunodeficiency. Frontiers in Immunology, 2015, 6, 157.	2.2	20
62	Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood, 2015, 125, 3996-4009.	0.6	410
63	CD21 and CD19 deficiency: Two defects in the same complex leading to different disease modalities. Clinical Immunology, 2015, 161, 120-127.	1.4	42
64	Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood. Haematologica, 2015, 100, 315-323.	1.7	38
65	Basal Ca2+ signaling is particularly increased in mutated chronic lymphocytic leukemia. Leukemia, 2015, 29, 321-328.	3.3	22
66	Quality assessment program for <scp>E</scp> uro <scp>F</scp> low protocols: Summary results of fourâ€year (2010–2013) quality assurance rounds. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 145-156.	1.1	144
67	Circulating Human CD27â^'IgA+ Memory B Cells Recognize Bacteria with Polyreactive Igs. Journal of Immunology, 2015, 195, 1417-1426.	0.4	99
68	New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood, 2015, 125, 3059-3068.	0.6	256
69	A mutation in the human tetraspanin CD81 gene is expressed as a truncated protein but does not enable CD19 maturation and cell surface expression. Journal of Clinical Immunology, 2015, 35, 254-263.	2.0	19
70	A Model for Predicting Effect of Treatment on Progression-Free Survival Using Minimal Residual Disease As a Surrogate Endpoint in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 720-720.	0.6	2
71	Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality. Oncotarget, 2015, 6, 42938-42951.	0.8	23
72	Analytical Validation of Patient-Specific PCR-Based MRD Assessment for Use As a Primary Endpoint in CLL Clinical Trials. Blood, 2015, 126, 2924-2924.	0.6	0

#	Article	IF	CITATIONS
73	T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS. Blood Cancer Journal, 2014, 4, e209-e209.	2.8	8
74	Lack of common TCRA and TCRB clonotypes in CD8+/TCRαβ+ T-cell large granular lymphocyte leukemia: a review on the role of antigenic selection in the immunopathogenesis of CD8+ T-LGL. Blood Cancer Journal, 2014, 4, e172-e172.	2.8	17
75	Defective B-cell memory in patients with Down syndrome. Journal of Allergy and Clinical Immunology, 2014, 134, 1346-1353.e9.	1.5	53
76	Thyrotropin Acts as a T-Cell Developmental Factor in Mice and Humans. Thyroid, 2014, 24, 1051-1061.	2.4	35
77	B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma. Blood, 2014, 124, 412-419.	0.6	48
78	Human CD19 and CD40L deficiencies impair antibody selection and differentially affect somatic hypermutation. Journal of Allergy and Clinical Immunology, 2014, 134, 135-144.e7.	1.5	71
79	B-cell development and functions and therapeutic options in adenosine deaminase–deficient patients. Journal of Allergy and Clinical Immunology, 2014, 133, 799-806.e10.	1.5	30
80	Genetic and epigenetic determinants mediate proneness of oncogene breakpoint sites for involvement in TCR translocations. Genes and Immunity, 2014, 15, 72-81.	2.2	3
81	The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS. Leukemia, 2014, 28, 189-192.	3.3	21
82	Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes. Journal of Allergy and Clinical Immunology, 2014, 133, 1124-1133.e1.	1.5	71
83	Minimal residual disease diagnostics in acute lymphoblastic leukaemia: impact of primer characteristics and size of junctional regions. British Journal of Haematology, 2014, 164, 451-453.	1.2	9
84	Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations. Leukemia, 2014, 28, 1747-1750.	3.3	13
85	Successful RAG1-SCID gene therapy depends on the level of RAG1 expression. Journal of Allergy and Clinical Immunology, 2014, 134, 242-243.	1.5	20
86	Persistent polyclonal B-cell lymphocytosis: extensively proliferated CD27+IgM+IgD+ memory B cells with a distinctive immunophenotype. Leukemia, 2014, 28, 1560-1564.	3.3	19
87	Deregulated WNT signaling in childhood T-cell acute lymphoblastic leukemia. Blood Cancer Journal, 2014, 4, e192-e192.	2.8	58
88	Human IgE+ B cells are derived from T cell–dependent and T cell–independent pathways. Journal of Allergy and Clinical Immunology, 2014, 134, 688-697.e6.	1.5	79
89	Recovery of the Normal B-Cell Compartment in Children Treated for B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3792-3792.	0.6	0
90	Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity. Journal of Allergy and Clinical Immunology, 2013, 131, 1367-1375.e9.	1.5	107

#	Article	IF	CITATIONS
91	No significant prognostic value of normal precursor <scp>B</scp> â€eell regeneration in paediatric acute myeloid leukaemia after induction treatment. British Journal of Haematology, 2013, 161, 861-864.	1.2	6
92	Applicability of a reproducible flow cytometry scoring system in the diagnosis of refractory cytopenia of childhood. Leukemia, 2013, 27, 1923-1925.	3.3	20
93	The MLL recombinome of acute leukemias in 2013. Leukemia, 2013, 27, 2165-2176.	3.3	393
94	Real-Time Quantitative (RQ-)PCR Approach to Quantify the Contribution of Proliferation to B Lymphocyte Homeostasis. Methods in Molecular Biology, 2013, 979, 133-145.	0.4	3
95	MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR. Methods in Molecular Biology, 2013, 971, 175-200.	0.4	48
96	Multicolor Flowcytometric Immunophenotyping Is a Valuable Tool for Detection of Intraocular Lymphoma. Ophthalmology, 2013, 120, 991-996.	2.5	54
97	Studying the Replication History of Human B Lymphocytes by Real-Time Quantitative (RQ)-PCR. Methods in Molecular Biology, 2013, 971, 113-122.	0.4	0
98	Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends in Biotechnology, 2013, 31, 415-425.	4.9	119
99	Combined TCRG and TCRA TREC analysis reveals increased peripheral T-lymphocyte but constant intra-thymic proliferative history upon ageing. Molecular Immunology, 2013, 53, 302-312.	1.0	14
100	Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia, 2013, 27, 635-641.	3.3	88
101	Breakpoint sites disclose the role of the V(D)J recombination machinery in the formation of T-cell receptor (TCR) and non-TCR associated aberrations in T-cell acute lymphoblastic leukemia. Haematologica, 2013, 98, 1173-1184.	1.7	31
102	Clinical Spectrum of LIG 4 Deficiency Is Broadened with Severe Dysmaturity, Primordial Dwarfism, and Neurological Abnormalities. Human Mutation, 2013, 34, 1611-1614.	1.1	34
103	The peripheral blood compartment in patient with Graves' disease: activated T lymphocytes and increased transitional and pre-naive mature B lymphocytes. Clinical and Experimental Immunology, 2013, 174, n/a-n/a.	1.1	20
104	Common variable immunodeficiency and idiopathic primary hypogammaglobulinemia: two different conditions within the same disease spectrum. Haematologica, 2013, 98, 1617-1623.	1.7	67
105	The Nuclear Effector of Wnt-Signaling, Tcf1, Functions as a T-Cell–Specific Tumor Suppressor for Development of Lymphomas. PLoS Biology, 2012, 10, e1001430.	2.6	67
106	EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia, 2012, 26, 2159-2171.	3.3	409
107	EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine. Leukemia, 2012, 26, 1899-1907.	3.3	85
108	Highly sensitive MRD tests for ALL based on the IKZF1 Δ3–6 microdeletion. Leukemia, 2012, 26, 1414-1416.	3.3	30

#	Article	IF	CITATIONS
109	The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia, 2012, 26, 255-264.	3.3	104
110	Morbidly Obese Human Subjects Have Increased Peripheral Blood CD4+ T Cells With Skewing Toward a Treg- and Th2-Dominated Phenotype. Diabetes, 2012, 61, 401-408.	0.3	163
111	Flow cytometric immunobead assay for fast and easy detection of PML–RARA fusion proteins for the diagnosis of acute promyelocytic leukemia. Leukemia, 2012, 26, 1976-1985.	3.3	27
112	The defect in humoral immunity in patients with Nijmegen breakage syndrome is explained by defects in peripheral B lymphocyte maturation. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 835-842.	1.1	26
113	EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia, 2012, 26, 1986-2010.	3.3	668
114	EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia, 2012, 26, 1908-1975.	3.3	738
115	The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation. Leukemia, 2012, 26, 1821-1828.	3.3	83
116	Capillary electrophoresis single-strand conformation analysis (CE-SSCA) for clonality detection in lymphoproliferative disorders. Journal of Hematopathology, 2012, 5, 83-89.	0.2	2
117	The EuroClonality website: information, education and support on clonality testing. Journal of Hematopathology, 2012, 5, 99-103.	0.2	2
118	Multiple clonal Ig/TCR products: implications for interpretation of clonality findings. Journal of Hematopathology, 2012, 5, 35-43.	0.2	33
119	Clonal antigen receptor gene PCR products outside the expected size range. Journal of Hematopathology, 2012, 5, 57-67.	0.2	8
120	Correct interpretation of Tâ€ALL oncogene expression relies on normal human thymocyte subsets as reference material. British Journal of Haematology, 2012, 157, 142-146.	1.2	1
121	New frontiers of primary antibody deficiencies. Cellular and Molecular Life Sciences, 2012, 69, 59-73.	2.4	22
122	B-cell replication history and somatic hypermutation status identify distinct pathophysiologic backgrounds in common variable immunodeficiency. Blood, 2011, 118, 6814-6823.	0.6	112
123	Standardization of DNA isolation from low cell numbers for chimerism analysis by PCR of short tandem repeats. Leukemia, 2011, 25, 1467-1470.	3.3	40
124	Canonical Wnt Signaling Regulates Hematopoiesis in a Dosage-Dependent Fashion. Cell Stem Cell, 2011, 9, 345-356.	5.2	277
125	Artemis splice defects cause atypical SCID and can be restored in vitro by an antisense oligonucleotide. Genes and Immunity, 2011, 12, 434-444.	2.2	27
126	IL-7R expression and IL-7 signaling confer a distinct phenotype on developing human B-lineage cells. Blood, 2011, 118, 2116-2127.	0.6	28

#	Article	IF	CITATIONS
127	Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood, 2011, 118, 2077-2084.	0.6	370
128	Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood, 2011, 118, 2150-2158.	0.6	331
129	Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia, 2011, 25, 254-258.	3.3	119
130	Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer. Leukemia, 2011, 25, 1471-1483.	3.3	78
131	Checkpoints of B cell differentiation: visualizing Ig entric processes. Annals of the New York Academy of Sciences, 2011, 1246, 11-25.	1.8	23
132	Dissection of B-Cell Development to Unravel Defects in Patients with a Primary Antibody Deficiency. Advances in Experimental Medicine and Biology, 2011, 697, 183-196.	0.8	10
133	The nature of circulating CD27+CD43+ B cells. Journal of Experimental Medicine, 2011, 208, 2565-2566.	4.2	89
134	PID Comes Full Circle: Applications of V(D)J Recombination Excision Circles in Research, Diagnostics and Newborn Screening of Primary Immunodeficiency Disorders. Frontiers in Immunology, 2011, 2, 12.	2.2	62
135	Antibody deficiency due to a missense mutation in CD19 demonstrates the importance of the conserved tryptophan 41 in immunoglobulin superfamily domain formation. Human Molecular Genetics, 2011, 20, 1854-1863.	1.4	31
136	Late Recurrence of Childhood T-Cell Acute Lymphoblastic Leukemia Frequently Represents a Second Leukemia Rather Than a Relapse: First Evidence for Genetic Predisposition. Journal of Clinical Oncology, 2011, 29, 1643-1649.	0.8	62
137	Harmonization of light scatter and fluorescence flow cytometry profiles obtained after staining peripheral blood leucocytes for cell surfaceâ€only versus intracellular antigens with the Fix & Permâ"¢ reagent. Cytometry Part B - Clinical Cytometry, 2010, 78B, 11-20.	0.7	7
138	Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood, 2010, 115, 3215-3223.	0.6	243
139	Loss of juxtaposition of RAG-induced immunoglobulin DNA ends is implicated in the precursor B-cell differentiation defect in NBS patients. Blood, 2010, 115, 4770-4777.	0.6	37
140	Wnt3a nonredundantly controls hematopoietic stem cell function and its deficiency results in complete absence of canonical Wnt signaling. Blood, 2010, 116, 496-497.	0.6	36
141	Estimating human age from T-cell DNA rearrangements. Current Biology, 2010, 20, R970-R971.	1.8	156
142	A novel radiosensitive SCID patient with a pronounced G2/M sensitivity. DNA Repair, 2010, 9, 365-373.	1.3	3
143	Human peripheral blood Bâ€cell compartments: A crossroad in Bâ€cell traffic. Cytometry Part B - Clinical Cytometry, 2010, 78B, S47-60.	0.7	258
144	The potential use of basigin (CD147) as a prognostic marker in Bâ€cell precursor acute lymphoblastic leukaemia. British Journal of Haematology, 2010, 150, 624-626.	1.2	1

#	Article	IF	CITATIONS
145	B-cell maturation and antibody responses in individuals carrying a mutated CD19 allele. Genes and Immunity, 2010, 11, 523-530.	2.2	34
146	Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia, 2010, 24, 521-535.	3.3	302
147	Genome-wide expression analysis of paired diagnosis–relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype. Leukemia, 2010, 24, 491-499.	3.3	48
148	Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia, 2010, 24, 1462-1469.	3.3	62
149	Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukemia treatment. Leukemia, 2010, 24, 903-907.	3.3	16
150	Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK. Leukemia, 2010, 24, 1617-1630.	3.3	40
151	Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia, 2010, 24, 1599-1606.	3.3	129
152	Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping. Leukemia, 2010, 24, 1927-1933.	3.3	131
153	IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia, 2010, 24, 1258-1264.	3.3	238
154	Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood, 2010, 115, 3206-3214.	0.6	685
155	Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay. Best Practice and Research in Clinical Haematology, 2010, 23, 333-345.	0.7	23
156	Genetic aberrations in paediatric acute leukaemias and implications for management of patients. Lancet Oncology, The, 2010, 11, 880-889.	5.1	82
157	CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. Journal of Clinical Investigation, 2010, 120, 1265-1274.	3.9	345
158	A DNA-PKcs mutation in a radiosensitive T–B– SCID patient inhibits Artemis activation and nonhomologous end-joining. Journal of Clinical Investigation, 2009, 119, 91-8.	3.9	220
159	Wnt3a deficiency irreversibly impairs hematopoietic stem cell self-renewal and leads to defects in progenitor cell differentiation. Blood, 2009, 113, 546-554.	0.6	171
160	Circulating CD21 ^{low} B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13451-13456.	3.3	308
161	Clinical heterogeneity can hamper the diagnosis of patients with ZAP70 deficiency. European Journal of Pediatrics, 2009, 168, 87-93.	1.3	103
162	Variation in the <i>IGFâ€l </i> gene is associated with lymphocyte subset counts in neonates: The Generation R Study. Clinical Endocrinology, 2009, 70, 53-59.	1.2	3

#	Article	IF	CITATIONS
163	<i>TACI</i> mutations and disease susceptibility in patients with common variable immunodeficiency. Clinical and Experimental Immunology, 2009, 156, 35-39.	1.1	46
164	Chromosome 14 copy number-dependent IGH gene rearrangement patterns in high hyperdiploid childhood B-cell precursor ALL: implications for leukemia biology and minimal residual disease analysis. Leukemia, 2009, 23, 870-876.	3.3	9
165	Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia, 2009, 23, 1073-1079.	3.3	137
166	New insights to the MLL recombinome of acute leukemias. Leukemia, 2009, 23, 1490-1499.	3.3	363
167	Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients. Leukemia, 2009, 23, 1106-1117.	3.3	75
168	Cluster analysis of genomic ETV6–RUNX1 (TEL–AML1) fusion sites in childhood acute lymphoblastic leukemia. Leukemia Research, 2009, 33, 1082-1088.	0.4	18
169	MRD Detection in Acute Lymphoblastic Leukemia Patients Using Ig/TCR Gene Rearrangements as Targets for Real-Time Quantitative PCR. Methods in Molecular Biology, 2009, 538, 115-150.	0.4	83
170	Fetal Growth Influences Lymphocyte Subset Counts at Birth: The Generation R Study. Neonatology, 2009, 95, 149-156.	0.9	17
171	Omenn's syndrome in cousins: different clinical course and identical RAG1 mutation. Pediatria Polska, 2009, 84, 367-372.	0.1	6
172	DNA-PKcs deficiency in human: long predicted, finally found. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 503-509.	1.1	58
173	Molecular Diagnostics of Primary Immunodeficiencies: Benefits and Future Challenges. Advances in Experimental Medicine and Biology, 2009, 634, 231-241.	0.8	6
174	Pitfalls in TCR gene clonality testing: teaching cases. Journal of Hematopathology, 2008, 1, 97-109.	0.2	76
175	Unique morphological spectrum of lymphomas in Nijmegen breakage syndrome (NBS) patients with high frequency of consecutive lymphoma formation. Journal of Pathology, 2008, 216, 337-344.	2.1	44
176	Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 834-846.	1.1	81
177	A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic Bâ€cell chronic lymphoproliferative disorders. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 1141-1150.	1.1	60
178	Gross Deletions Involving IGHM, BTK, or Artemis: A Model for Genomic Lesions Mediated by Transposable Elements. American Journal of Human Genetics, 2008, 82, 320-332.	2.6	77
179	Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?. Leukemia, 2008, 22, 1849-1852.	3.3	28
180	Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia, 2008, 22, 771-782.	3.3	339

#	Article	IF	CITATIONS
181	Non-specific amplification of patient-specific lg/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring. Leukemia, 2008, 22, 641-644.	3.3	36
182	BMI1 as oncogenic candidate in a novel TCRB-associated chromosomal aberration in a patient with TCRγδ+ T-cell acute lymphoblastic leukemia. Leukemia, 2008, 22, 1266-1267.	3.3	8
183	The 3D Structure of the Immunoglobulin Heavy-Chain Locus: Implications for Long-Range Genomic Interactions. Cell, 2008, 133, 265-279.	13.5	271
184	Involvement of Artemis in nonhomologous end-joining during immunoglobulin class switch recombination. Journal of Experimental Medicine, 2008, 205, 3031-3040.	4.2	41
185	Perinatal Stress Influences Lymphocyte Subset Counts in Neonates. The Generation R Study. Pediatric Research, 2008, 63, 292-298.	1.1	23
186	Erratum to "New Insights and Unresolved Issues Regarding Insertional Mutagenesis in X-linked SCID Gene Therapy― Molecular Therapy, 2008, 16, 218.	3.7	0
187	Antibody-Deficiency and Acute Nephritic Syndrome in a Patient with Homozygous Disruption of the CD81 Gene. Blood, 2008, 112, 83-83.	0.6	1
188	Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion. Journal of Experimental Medicine, 2007, 204, 645-655.	4.2	279
189	New Insights and Unresolved Issues Regarding Insertional Mutagenesis in X-linked SCID Gene Therapy. Molecular Therapy, 2007, 15, 1910-1916.	3.7	92
190	Immunoglobulin/T-cell receptor clonality diagnostics. Expert Opinion on Medical Diagnostics, 2007, 1, 451-461.	1.6	34
191	Homeostatic and Maturation-associated Proliferation in the Peripheral B-Cell Compartment. Cell Cycle, 2007, 6, 2890-2895.	1.3	20
192	CD33 expression and P-glycoprotein–mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood, 2007, 109, 4168-4170.	0.6	176
193	Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL. Blood, 2007, 110, 388-392.	0.6	47
194	Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood, 2007, 110, 3112-3121.	0.6	157
195	The Human Androgen Receptor X-Chromosome Inactivation Assay for Clonality Diagnostics of Natural Killer Cell Proliferations. Journal of Molecular Diagnostics, 2007, 9, 337-344.	1.2	27
196	Improved reliability of lymphoma diagnostics via PCR-based clonality testing: — Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia, 2007, 21, 201-206.	3.3	279
197	Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia, 2007, 21, 207-214.	3.3	292
198	Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia, 2007, 21, 215-221.	3.3	222

#	Article	IF	CITATIONS
199	Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 2007, 21, 222-229.	3.3	143
200	Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes. Leukemia, 2007, 21, 230-237.	3.3	55
201	Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia, 2007, 21, 706-713.	3.3	139
202	Ectopic retroviral expression of LMO2, but not IL2Rî³, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Leukemia, 2007, 21, 754-763.	3.3	71
203	Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The â€`big sister' of the infant disease?. Leukemia, 2007, 21, 642-646.	3.3	21
204	Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia, 2007, 21, 633-641.	3.3	102
205	Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia, 2007, 21, 604-611.	3.3	626
206	Childhood secondary ALL after ALL treatment. Leukemia, 2007, 21, 1431-1435.	3.3	26
207	Role of Artemis in DSB repair and guarding chromosomal stability following exposure to ionizing radiation at different stages of cell cycle. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 615, 111-124.	0.4	48
208	Two Patients with Complete Defects in Interferon Gamma Receptor-Dependent Signaling. Journal of Clinical Immunology, 2007, 27, 490-496.	2.0	25
209	Novel insights into the development of T-cell acute lymphoblastic leukemia. Current Hematologic Malignancy Reports, 2007, 2, 176-182.	1.2	7
210	Comparative Analysis of Gene Expression Profiles between Diagnosis and Relapse of Childhood Acute Lymphoblastic Leukemia Blood, 2007, 110, 2809-2809.	0.6	0
211	Detection of Genomic Lesions in Childhood Precursor-B Cell ALL in Diagnosis and Relapse Samples Using High Resolution Genomic Profiling Blood, 2007, 110, 995-995.	0.6	1
212	Late Relapses of Childhood T-ALL Are Frequently Second T-ALL Blood, 2007, 110, 1435-1435.	0.6	0
213	Human thymus contains multipotent progenitors with T/B lymphoid, myeloid, and erythroid lineage potential. Blood, 2006, 107, 3131-3137.	0.6	94
214	Molecular Monitoring of Lymphoma. , 2006, , 83-109.		1
215	Immunoglobulin and T-cell receptor gene rearrangements. , 2006, , 210-234.		2
216	Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood, 2006, 107, 3045-3052.	0.6	254

#	Article	IF	CITATIONS
217	Impact of two independent bone marrow samples on minimal residual disease monitoring in childhood acute lymphoblastic leukaemia. British Journal of Haematology, 2006, 133, 382-388.	1.2	20
218	Is IL2RG oncogenic in T-cell development?. Nature, 2006, 443, E5-E5.	13.7	48
219	TCRγδ+ large granular lymphocyte leukemias reflect the spectrum of normal antigen-selected TCRγδ+ T-cells. Leukemia, 2006, 20, 505-513.	3.3	86
220	Notch and Wnt signaling in T-lymphocyte development and acute lymphoblastic leukemia. Leukemia, 2006, 20, 1197-1205.	3.3	80
221	Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. Leukemia, 2006, 20, 1385-1392.	3.3	47
222	Identification of Notch target genes in uncommitted T-cell progenitors: no direct induction of a T-cell specific gene program. Leukemia, 2006, 20, 1967-1977.	3.3	53
223	Clonal T- and natural killer-cell large granular lymphocyte proliferations in a single patient established by array-based comparative genomic hybridization analysis. Leukemia, 2006, 20, 2212-2214.	3.3	5
224	Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. Leukemia Research, 2006, 30, 98-102.	0.4	33
225	Effects of Delta1 and Jagged1 on Early Human Hematopoiesis: Correlation with Expression of Notch Signaling-Related Genes in CD34+Cells. Stem Cells, 2006, 24, 1328-1337.	1.4	43
226	Wnt signaling in the thymus is regulated by differential expression of intracellular signaling molecules. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3322-3326.	3.3	105
227	An Antibody-Deficiency Syndrome Due to Mutations in theCD19Gene. New England Journal of Medicine, 2006, 354, 1901-1912.	13.9	517
228	Flow-cytometric immunophenotyping of normal and malignant lymphocytes. Clinical Chemistry and Laboratory Medicine, 2006, 44, 775-96.	1.4	55
229	Maximum significance clustering of oligonucleotide microarrays. Bioinformatics, 2006, 22, 326-331.	1.8	9
230	Minimal residual disease. , 2006, , 679-706.		1
231	Relationship between CD33 Expression, P-Glycoprotein-Mediated Drug Efflux, and Clinical Outcome in Patients Treated in Phase II Trials with Gemtuzumab Ozogamicin Monotherapy Blood, 2006, 108, 2324-2324.	0.6	3
232	Split-signal FISH for detection of chromosome aberrations. Hematology, 2005, 10, 66-72.	0.7	6
233	Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 449-454.	3.3	175
234	Disruption of the BCL11B gene through inv(14)(q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-type BCL11B transcripts in T-ALL. Leukemia, 2005, 19, 201-208.	3.3	113

#	Article	IF	CITATIONS
235	Purity for clarity: the need for purification of tumor cells in DNA microarray studies. Leukemia, 2005, 19, 618-627.	3.3	35
236	Identification of e19a2 BCR–ABL fusions (μ-BCR breakpoints) at the DNA level by ligation-mediated PCR. Leukemia, 2005, 19, 1292-1295.	3.3	11
237	CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. Leukemia, 2005, 19, 1948-1957.	3.3	110
238	Efficient and easy detection of MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts by multiplex real-time quantitative RT-PCR in TaqMan and LightCycler. Leukemia, 2005, 19, 2016-2018.	3.3	35
239	Quantification of CBFB-MYH11 fusion gene levels in paired peripheral blood and bone marrow samples by real-time PCR. Leukemia, 2005, 19, 1988-1990.	3.3	13
240	Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer, 2005, 104, 1442-1452.	2.0	429
241	lg Gene Rearrangement Steps Are Initiated in Early Human Precursor B Cell Subsets and Correlate with Specific Transcription Factor Expression. Journal of Immunology, 2005, 175, 5912-5922.	0.4	158
242	New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. Journal of Experimental Medicine, 2005, 201, 1715-1723.	4.2	318
243	Immunogenotype Changes Prevail in Relapses of Young Children with TEL-AML1-Positive Acute Lymphoblastic Leukemia and Derive Mainly from Clonal Selection. Clinical Cancer Research, 2005, 11, 7720-7727.	3.2	33
244	Age-related changes in the cellular composition of the thymus in children. Journal of Allergy and Clinical Immunology, 2005, 115, 834-840.	1.5	71
245	BIOMED-2 Multiplex Immunoglobulin/T-Cell Receptor Polymerase Chain Reaction Protocols Can Reliably Replace Southern Blot Analysis in Routine Clonality Diagnostics. Journal of Molecular Diagnostics, 2005, 7, 495-503.	1.2	85
246	A new type of radiosensitive T-B-NK+ severe combined immunodeficiency caused by a LIG4 mutation. Journal of Clinical Investigation, 2005, 116, 137-145.	3.9	160
247	Immunoglobulin Light Chain Gene Rearrangements in Childhood Precursor-B-ALL: Immunobiological Characteristics and Applicability for the Detection of Minimal Residual Disease Blood, 2005, 106, 1442-1442.	0.6	0
248	Unraveling the Consecutive Recombination Events in the Human <i>IGK</i> Locus. Journal of Immunology, 2004, 173, 3878-3888.	0.4	28
249	Wnt Target Genes Identified by DNA Microarrays in Immature CD34+ Thymocytes Regulate Proliferation and Cell Adhesion. Journal of Immunology, 2004, 172, 1099-1108.	0.4	99
250	High incidence and unique features of antigen receptor gene rearrangements in TEL–AML1-positive leukemias. Leukemia, 2004, 18, 84-91.	3.3	29
251	Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia, 2004, 18, 316-325.	3.3	131
252	Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia, 2004, 18, 709-719.	3.3	88

#	Article	IF	CITATIONS
253	Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease – a study within the Europe Against Cancer Program. Leukemia, 2004, 18, 884-886.	3.3	40
254	Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia. Leukemia, 2004, 18, 895-908.	3.3	73
255	High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients. Leukemia, 2004, 18, 983-988.	3.3	106
256	Validation of BIOMED-2 multiplex PCR tubes for detection of TCRB gene rearrangements in T-cell malignancies. Leukemia, 2004, 18, 1531-1538.	3.3	44
257	TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse. Leukemia, 2004, 18, 1971-1980.	3.3	58
258	Acute lymphoblastic leukemia followed by a clonally-unrelated EBV-positive non-Hodgkin lymphoma and a clonally-related myelomonocytic leukemia cutis. Pediatric Blood and Cancer, 2004, 42, 343-349.	0.8	11
259	Pulmonary Mycobacterium avium intracellulare Infection in an Immunocompetent Child. Pediatric Infectious Disease Journal, 2004, 23, 892.	1.1	4
260	Vδ2-Jα rearrangements are frequent in precursor-B–acute lymphoblastic leukemia but rare in normal lymphoid cells. Blood, 2004, 103, 3798-3804.	0.6	71
261	Differential Effects of Delta1 and Jagged1 in Early Human Myelopoiesis: Correlation with Distinct Gene-Expression Profiles in CD34+ Cells Blood, 2004, 104, 2786-2786.	0.6	Ο
262	CALM-AF10 Positive T-ALLs Show a Pattern of Expression Similar to MLL-Translocated Acute Leukemias Blood, 2004, 104, 1108-1108.	0.6	1
263	Identification of a new cluster of T-cell receptor delta recombining elements. Immunology, 2003, 108, 16-23.	2.0	1
264	Spectrum of T-large granular lymphocyte lymphoproliferations: ranging from expanded activated effector T cells to T-cell leukaemia. British Journal of Haematology, 2003, 123, 561-562.	1.2	15
265	Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplantation, 2003, 32, 849-851.	1.3	79
266	Inhibition affecting RQ-PCR-based assessment of minimal residual disease in acute lymphoblastic leukemia: reversal by addition of bovine serum albumin. Leukemia, 2003, 17, 268-270.	3.3	22
267	Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia, 2003, 17, 1013-1034.	3.3	485
268	Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications. Leukemia, 2003, 17, 1398-1403.	3.3	38
269	DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers. Leukemia, 2003, 17, 1324-1332.	3.3	74
270	Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease. Leukemia, 2003, 17, 1834-1844.	3.3	58

#	Article	IF	CITATIONS
271	Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of second T-ALL. Leukemia, 2003, 17, 2149-2156.	3.3	69
272	Prenatal origin of hyperdiploid acute lymphoblastic leukemia in identical twins. Leukemia, 2003, 17, 2202-2206.	3.3	84
273	Standardization and quality control studies of â€~real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program. Leukemia, 2003, 17, 2318-2357.	3.3	1,359
274	Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using â€real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia, 2003, 17, 2474-2486.	3.3	806
275	Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 2003, 17, 2257-2317.	3.3	2,788
276	Allelotype analysis in relapsed childhood acute lymphoblastic leukemia. Oncogene, 2003, 22, 6970-6976.	2.6	14
277	Classification systems for acute and chronic leukaemias. Best Practice and Research in Clinical Haematology, 2003, 16, 561-582.	0.7	42
278	Clonality analysis for antigen receptor genes: Preliminary results from the biomed-2 concerted action PL 96-3936. Human Pathology, 2003, 34, 359-361.	1.1	21
279	Radiosensitive SCID patients with Artemis gene mutations show a complete B-cell differentiation arrest at the pre-B-cell receptor checkpoint in bone marrow. Blood, 2003, 101, 1446-1452.	0.6	93
280	Composition of Precursor B-Cell Compartment in Bone Marrow from Patients with X-Linked Agammaglobulinemia Compared with Healthy Children. Pediatric Research, 2002, 51, 159-168.	1.1	84
281	Acute Lymphoblastic Leukemia. Hematology American Society of Hematology Education Program, 2002, 2002, 162-192.	0.9	92
282	Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. Leukemia, 2002, 16, 368-375.	3.3	58
283	Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B–ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood, 2002, 99, 2315-2323.	0.6	155
284	Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia, 2002, 16, 928-936.	3.3	120
285	Unraveling of the Polymorphic Cλ2-Cλ3 Amplification and the Ke+Ozâ^' Polymorphism in the Human Igλ Locus. Journal of Immunology, 2002, 169, 271-276.	0.4	13
286	Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. Best Practice and Research in Clinical Haematology, 2002, 15, 37-57.	0.7	59
287	Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood, 2002, 99, 4386-4393.	0.6	150
288	Quantification of newly developed T cells in mice by real-time quantitative PCR of T-cell receptor rearrangement excision circles. Experimental Hematology, 2002, 30, 745-750.	0.2	36

#	Article	IF	CITATIONS
289	Biased Igλ expression in hypermutated IgD multiple myelomas does not result from receptor revision. Leukemia, 2002, 16, 1358-1361.	3.3	12
290	T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia, 2002, 16, 1372-1380.	3.3	107
291	Detection of clonal EBV episomes in lymphoproliferations as a diagnostic tool. Leukemia, 2002, 16, 1572-1573.	3.3	11
292	Immunoglobulin light chain gene rearrangements display hierarchy in absence of selection for functionality in precursor-B-ALL. Leukemia, 2002, 16, 1448-1453.	3.3	22
293	Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia, 2002, 16, 1432-1436.	3.3	129
294	Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia, 2002, 16, 1627-1636.	3.3	217
295	XLA patients with BTK splice-site mutations produce low levels of wild-type BTK transcripts. Journal of Clinical Immunology, 2002, 22, 306-318.	2.0	29
296	The immunophenotypic and immunogenotypic B-cell differentiation arrest in bone marrow of RAG-deficient SCID patients corresponds to residual recombination activities of mutated RAG proteins. Blood, 2002, 100, 2145-52.	0.6	64
297	Minimal residual disease in leukaemia patients. Lancet Oncology, The, 2001, 2, 409-417.	5.1	217
298	Ordered recombination of immunoglobulin light chain genes occurs at the IGK locus but seems less strict at theIGL locus. Blood, 2001, 97, 1001-1008.	0.6	65
299	Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse. Journal of Clinical Oncology, 2001, 19, 3244-3254.	0.8	837
300	Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood, 2001, 97, 3197-3204.	0.6	314
301	Molecular and flow cytometric analysis of the Vβ repertoire for clonality assessment in mature TCRαβ T-cell proliferations. Blood, 2001, 98, 165-173.	0.6	230
302	Basic helix-loop-helix proteins E2A and HEB induce immature T-cell receptor rearrangements in nonlymphoid cells. Blood, 2001, 98, 2456-2465.	0.6	63
303	T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation. Journal of Molecular Medicine, 2001, 79, 631-640.	1.7	293
304	Flow cytometric immunophenotyping in the diagnosis and follow-up of immunodeficient children. European Journal of Pediatrics, 2001, 160, 583-591.	1.3	13
305	SIHONSCORE: a scoring system for external quality control of leukaemia/lymphoma immunophenotyping measuring all analytical phases of laboratory performance. British Journal of Haematology, 2001, 112, 337-343.	1.2	9
306	Two consecutive immunophenotypic switches in a child with immunogenotypically stable acute leukaemia. British Journal of Haematology, 2001, 113, 757-762.	1.2	18

#	Article	IF	CITATIONS
307	Low frequency of reverse transcription polymerase chain reaction-detectable chromosome aberrations in relapsed acute myeloid leukaemia: implications for detection of minimal residual disease. British Journal of Haematology, 2001, 113, 1076-1089.	1.2	5
308	Clearance of maternal leukaemic cells in a neonate. British Journal of Haematology, 2001, 114, 104-106.	1.2	29
309	Molecular discrimination between relapsed and secondary acute lymphoblastic leukemia: Proposal for an easy strategy. Medical and Pediatric Oncology, 2001, 36, 352-358.	1.0	32
310	Reviewing Omenn syndrome. European Journal of Pediatrics, 2001, 160, 718-725.	1.3	99
311	Immunoglobulin lambda isotype gene rearrangements in B cell malignancies. Leukemia, 2001, 15, 121-127.	3.3	20
312	BIOMED-1 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. Leukemia, 2001, 15, 1185-1192.	3.3	128
313	The presence of somatic mutations in immunoglobulin genes of B cell acute lymphoblastic leukemia (ALL-L3) supports assignment as Burkitt's leukemia–lymphoma rather than B-lineage ALL. Leukemia, 2001, 15, 1141-1143.	3.3	14
314	T-lymphocytes in bone marrow samples of children with acute lymphoblastic leukemia during and after chemotherapy might hamper PCR-based minimal residual disease studies. Leukemia, 2001, 15, 1301-1302.	3.3	22
315	Response to Macintyre et al. Leukemia, 2001, 15, 1303-1303.	3.3	0
316	Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia, 2001, 15, 1485-1487.	3.3	91
317	Precursor-B-ALL with DH–JH gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia, 2001, 15, 1415-1423.	3.3	86
318	The role of molecular analysis of immunoglobulin and T cell receptor gene rearrangements in the diagnosis of lymphoproliferative disorders. Journal of Clinical Pathology, 2001, 54, 565-567.	1.0	22
319	Flow cytometric analysis of the V? repertoire in healthy controls. Cytometry, 2000, 40, 336-345.	1.8	174
320	Genetic variation in ICF syndrome: Evidence for genetic heterogeneity. Human Mutation, 2000, 16, 509-517.	1.1	92
321	Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease. British Journal of Haematology, 2000, 110, 139-146.	1.2	95
322	Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nature Medicine, 2000, 6, 1036-1042.	15.2	384
323	BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia, 2000, 14, 816-825.	3.3	104
324	Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy. Leukemia, 2000, 14, 688-695.	3.3	73

#	Article	IF	CITATIONS
325	T cell receptor gamma (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia reflect â€~end-stage' recombinations: implications for minimal residual disease monitoring. Leukemia, 2000, 14, 1208-1214.	3.3	52
326	Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia, 2000, 14, 1426-1435.	3.3	190
327	Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia, 2000, 14, 1939-1943.	3.3	105
328	E2A and EBF Act in Synergy with the V(D)J Recombinase to Generate a Diverse Immunoglobulin Repertoire in Nonlymphoid Cells. Molecular Cell, 2000, 5, 343-353.	4.5	192
329	Oligoclonal Gammopathy in Phenotypic Diarrhea. Journal of Pediatric Gastroenterology and Nutrition, 2000, 30, 349.	0.9	10
330	Autoimmune Lymphoproliferative Syndrome (ALPS) in a Child from Consanguineous Parents: A Dominant or Recessive Disease?. Pediatric Research, 2000, 47, 336-343.	1.1	55
331	Longitudinal Survey of Lymphocyte Subpopulations in the First Year of Life. Pediatric Research, 2000, 47, 528-537.	1.1	103
332	N-terminal truncated human RAG1 proteins can direct T-cell receptor but not immunoglobulin gene rearrangements. Blood, 2000, 96, 203-209.	0.6	0
333	TCR Gene Rearrangements and Expression of the Pre-T Cell Receptor Complex During Human T-Cell Differentiation. Blood, 1999, 93, 3033-3043.	0.6	116
334	The 782C → T (T254M) XHIM Mutation: Lack of a Tight Phenotype-Genotype Relationship. Blood, 1999, 94, 1488-1490.	0.6	8
335	Correction for erythroid cell contamination in microassay for immunophenotyping of neonatal lymphocytes. Archives of Disease in Childhood: Fetal and Neonatal Edition, 1999, 80, F226-F229.	1.4	11
336	Immunophenotypical detection of minimal residual disease in acute leukemia. Critical Reviews in Oncology/Hematology, 1999, 32, 175-185.	2.0	37
337	Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL. British Journal of Haematology, 1999, 104, 695-705.	1.2	40
338	Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemia. Leukemia, 1999, 13, 110-118.	3.3	328
339	Immunophenotypic and immunogenotypic characteristics of TCRγÎ′+ T cell acute lymphoblastic leukemia. Leukemia, 1999, 13, 206-214.	3.3	53
340	Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease. Leukemia, 1999, 13, 196-205.	3.3	156
341	Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia, 1999, 13, 419-427.	3.3	205
342	Detection of T cell receptor beta (TCRB) gene rearrangement patterns in T cell malignancies by Southern blot analysis. Leukemia, 1999, 13, 965-974.	3.3	56

#	Article	IF	CITATIONS
343	Suitable DNA isolation method for the detection of minimal residual disease by PCR techniques. Leukemia, 1999, 13, 1298-1299.	3.3	38
344	Easy detection of all T cell receptor gamma (TCRG) gene rearrangements by Southern blot analysis: recommendations for optimal results. Leukemia, 1999, 13, 1620-1626.	3.3	29
345	Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia, 1999, 13, 1901-1928.	3.3	1,038
346	Rapid and sensitive detection of all types of MLL gene translocations with a single FISH probe set. Leukemia, 1999, 13, 2107-2113.	3.3	52
347	Analysing the developing lymphocyte system of neonates and infants. European Journal of Pediatrics, 1999, 158, 611-617.	1.3	21
348	Disruption of αβ but not of γδT cell development by overexpression of the helix–loop–helix protein Id3 in committed T cell progenitors. EMBO Journal, 1999, 18, 2793-2802.	3.5	91
349	Induction of clinical remission in T-large granular lymphocyte leukemia with cyclosporin A, monitored by use of immunophenotyping with Vβ antibodies. Leukemia, 1998, 12, 150-154.	3.3	29
350	Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease. Leukemia, 1998, 12, 1081-1088.	3.3	89
351	Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia, 1998, 12, 2006-2014.	3.3	306
352	Early stages in the development of human T, natural killer and thymic dendritic cells. Immunological Reviews, 1998, 165, 75-86.	2.8	168
353	Intensified therapy for infants with acute lymphoblastic leukemia. Cancer, 1998, 83, 1055-1057.	2.0	3
354	Lymphoma with multi-gene rearrangement on the level of immunoglobulin heavy chain, light chain, and T-cell receptor β chain. , 1998, 59, 99-100.		11
355	Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet, The, 1998, 352, 1731-1738.	6.3	876
356	Longitudinal follow-up of blood lymphocyte subpopulations from birthto 1 year of age. Journal of Pediatrics, 1998, 133, 586-588.	0.9	11
357	Localization of the ICF Syndrome to Chromosome 20 by Homozygosity Mapping. American Journal of Human Genetics, 1998, 63, 803-809.	2.6	56
358	PJA-BP expression and TCR delta deletion during human T cell differentiation International Immunology, 1998, 10, 1873-1880.	1.8	10
359	Granulomatous Slack Skin. Dermatology, 1998, 196, 382-391.	0.9	84
360	Characterization of ABF-1, a Novel Basic Helix-Loop-Helix Transcription Factor Expressed in Activated B Lymphocytes. Molecular and Cellular Biology, 1998, 18, 3130-3139.	1.1	64

#	Article	IF	CITATIONS
361	Immunophenotyping of blood lymphocytes in childhoodReference values for lymphocyte subpopulations. Journal of Pediatrics, 1997, 130, 388-393.	0.9	661
362	Cranial irradiation is the major cause of learning problems in children treated for leukemia and lymphoma: a comparative study. Leukemia, 1997, 11, 1197-1200.	3.3	47
363	Flow cytometric detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes: testing of a new fixation-permeabilization solution. Leukemia, 1997, 11, 2208-2210.	3.3	14
364	Four aged siblings with B cell chronic lymphocytic leukemia. Leukemia, 1997, 11, 2060-2065.	3.3	21
365	Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia, 1997, 11, 2192-2199.	3.3	196
366	Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual disease. Leukemia, 1997, 11, 2200-2207.	3.3	81
367	Slaging of Sézary syndrome with somatostatin receptor scintigraphy. British Journal of Dermatology, 1996, 134, 178-179.	1.4	6
368	Familial disseminated atypical mycobacterial infection in childhood. Lancet, The, 1995, 345, 993.	6.3	4
369	Rearrangements of the human TCRD-deleting elements. Immunogenetics, 1994, 40, 70-75.	1.2	13
370	The scid mouse environment causes immunophenotypic changes in human immature T-cell lines. International Journal of Cancer, 1994, 56, 546-551.	2.3	8
371	The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. European Journal of Immunology, 1993, 23, 3109-3114.	1.6	199
372	Antigen Receptors on T and B Lymphocytes: Parallels in Organization and Function. Immunological Reviews, 1993, 132, 49-84.	2.8	48
373	Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes Journal of Experimental Medicine, 1993, 177, 965-977.	4.2	125
374	Small-Cell Undifferentiated (Neuroendocrine) Carcinoma of the Cecum in a Child with Common Variable Immunodeficiency. Journal of Pediatric Hematology/Oncology, 1993, 15, 258-261.	0.3	14
375	The B29 and mb-1 polypeptides are differentially expressed during human B cell differentiation. European Journal of Immunology, 1992, 22, 2753-2756.	1.6	62
376	Expression of mdr1 and mdr3 multidrug-resistance genes in hairy cell leukaemia. European Journal of Cancer & Clinical Oncology, 1991, 27, 297-298.	0.9	10
377	Abnormal Signal Transduction in a Patient with Severe Combined Immunodeficiency Disease. Pediatric Research, 1991, 29, 306-309.	1.1	10
378	Trimetrexate efficacy and pharmacokinetics during treatment of refractory Pneumocystis carinii pneumonia in an infant with severe combined immunodeficiency disease. Pediatric Infectious Disease Journal, 1990, 9, 212-214.	1.1	5

#	Article	IF	CITATIONS
379	Immunological Marker Analysis of Mitogen-Induced Proliferating Lymphocytes Using Brd U Incorporation or Screening of Metaphases Scandinavian Journal of Immunology, 1990, 32, 687-694.	1.3	11
380	BMA031, a monoclonal antibody suited to identify the T-cell receptor αβ/CD3 complex on viable human T lymphocytes in normal and disease states. Human Immunology, 1990, 29, 175-188.	1.2	37
381	Repertoire selection of human $\hat{I}^{3}\hat{I}$ T cells. Research in Immunology, 1990, 141, 663-668.	0.9	5
382	Expression of the myeloid differentiation antigen CD33 depends on the presence of human chromosome 19 in human-mouse hybrids. Annals of Human Genetics, 1990, 54, 115-119.	0.3	6
383	Human immunodeficiency virus infection studied in CD4-expressing human-murine T-cell hybrids. Virology, 1989, 168, 267-273.	1.1	67
384	Non-random expression of T cell receptor γ and δ variable gene segments in functional T lymphocyte clones from human peripheral blood. European Journal of Immunology, 1989, 19, 1559-1568.	1.6	91
385	Time-history of the malignant population in the peripheral blood of a child with T-cell acute lymphoblastic leukemia. Computers and Mathematics With Applications, 1989, 18, 929-936.	1.4	3
386	Invasive Aspergillus infection in chronic granulomatous disease: Treatment with itraconazole. Journal of Pediatrics, 1989, 115, 1016-1019.	0.9	26
387	Phenotype of Blood Monocytes and Alveolar Macrophages in Interstitial Lung Disease. Chest, 1989, 95, 574-577.	0.4	38
388	TdT positive B-cell acute lymphoblastic leukaemia (B-ALL) without Burkitt characteristics. British Journal of Haematology, 1988, 68, 423-426.	1.2	31
389	Oligoclonal T Cell Proliferative Disorder in Combined Immunodeficiency. Pediatric Research, 1988, 24, 622-627.	1.1	8
390	Distinct molecular forms of human T cell receptor gamma/delta detected on viable T cells by a monoclonal antibody Journal of Experimental Medicine, 1988, 167, 1625-1644.	4.2	167
391	Bronchoalveolar Lavage in Extrapulmonary Sarcoidosis. Chest, 1988, 94, 115-118.	0.4	13
392	The gene encoding the epsilon subunit of the T3/T-cell receptor complex maps to chromosome 11 in humans and to chromosome 9 in mice Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 1664-1668.	3.3	70
393	Analysis of T cell receptor-gene rearrangement in T cells from the cerebrospinal fluid of patients with multiple sclerosis. Journal of Neuroimmunology, 1987, 15, 243-249.	1.1	21
394	Pulmonary alveolar proteinosis: Determination of prostaglandins and leukotrienes in lavage fluid. Lung, 1987, 165, 79-89.	1.4	3
395	Two types of gamma T cell receptors expressed by T cell acute lymphoblastic leukemias. European Journal of Immunology, 1987, 17, 1719-1728.	1.6	39
396	Phenotypic and genotypic characteristics of the human prothymocyte. Immunologic Research, 1987, 6, 250-262.	1.3	1

#	Article	IF	CITATIONS
397	Expression of the human immunoglobulin heavy chain gene of the 14q+ chromosome in a t(8;14)-positive Burkitt lymphoma cell line demonstrated in somatic cell hybrids. Cancer Genetics and Cytogenetics, 1986, 19, 321-330.	1.0	1
398	Alveolitis in an Asymptomatic Pigeon Breeder. Chest, 1985, 87, 272.	0.4	0
399	Bilateral Exudative Pleuritis, an Unusual Pulmonary Onset of Mixed Connective Tissue Disease. Respiration, 1985, 48, 164-167.	1.2	15
400	Triple immunological staining with colloidal gold, fluorescein and rhodamine as labels. Journal of Immunological Methods, 1985, 80, 1-6.	0.6	35
401	Confirmation of the assignment of the gene coding for the BA-2 antigen to human chromosome 12. Human Genetics, 1984, 68, 351-352.	1.8	4
402	Corticosteroids and the humoral immune response of mice. Cellular Immunology, 1978, 41, 52-61.	1.4	13
403	Immunoglobulin and T-cell receptor gene rearrangements. , 0, , 113-134.		0
404	Minimal residual disease. , 0, , 632-659.		0